Redeye embraces another quarter of continuous sales growth and key activities in its clinical trial ...
Redeye retains its positive view of Infracom following its Q3 report.
Redeye states the Q3 report was strong across the board.
Redeye is encouraged to see the announcement of a Coating Service order for electrolysis plates.
Ferronordic's Q3 report was better than we expected, driven by good sales mix in Russia/CIS.
Redeye retains its positive view on Speqta following a solid Q3 report.
Redeye endorses today’s news from Heliospectra, an order of USD780,000 from an American AgTech compa...
Redeye provides a short comment on SenzaGen’s acquisition of ToxHub, an Italian toxicology services ...
Supply chain issues and shortages continue to hit Boule Missed sales by 13% and EBIT by 80% vs.
Angler Gaming ökar kraftigt omsättning och rörelseresultat sekventiellt vilket vittnar om ett trendb...
Prostatype are making good European launch progress with clinical evaluations, ongoing evaluations a...
Large net profit beat from loan loss reversals… … and exploitation of deferred tax asset PBLL miss l...
Ett svagt kvartal Bolagets nettoomsättning uppgick till 1,0 mkr (3,6 mkr) och rörelseresultatet blev...
Ultimovacs’ Q322 results highlighted an eventful period for the development of the company’s lead ca...
Omsättning något över våra estimat Omsättningen uppgick till EUR 12,9m vs våra estimat om EUR 12,3, ...
Q3 i korthet Nettoresultatet var -23 mkr (-36) jämfört med vår förväntan om -56 mkr.
Redey is happy to see Image Systems delivering very strong Q3 numbers, with earnings and margins at ...
EBIT SEK 37m vs. ABGSCe SEK 41m Disappointing guidance for Q4’22 Conference call at 09.
IFreja’s Q3 report confirmed our positive views and our concerns.
Redeye leaves a short comment on today’s news that Xbrane and STADA have secured EU approval for Xim...
